Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
CKD G3-G4 of other etiologiesADPKDCKD G3-G4(n = 44)Other etiologiesCKD G3-G4(n = 14)P valueAge, year47.00 [38.50, 54.00]40.50 [37.25, 44.25]0.086Clinical dataSex, F/M14/30 (31.8/68.2)7/7 (50.0/50.0)0.361BMI, kg/m226.88 [24.21, 28.98]23.77 [21.97, 28.73]0.143Creatinine, mg/dL1.77 [1.48, 2.24]1.81 [1.63, 2.00]0.419ACR, mg/g38.30 [11.36, 148.76]250.36 [42.91, 814.85] 0.028 CRP, mg/dL1.19 [0.88, 2.74]1.02 [0.84, 1.57]0.741Bone metabolismCalcium, mg/dL9.60 [9.40, 9.85]9.50 [9.22, 9.88]0.551Phosphate, mg/dL3.10 [2.75, 3.45]3.15 [2.87, 3.58]0.413Magnesium, mg/dL1.90 [1.80, 2.10]1.90 [1.90, 2.00]0.828PTH, pg/mL56.80 [42.15, 97.55]55.20 [35.88, 99.05]0.853FGF23 intact, pg/mL91.97 [61.44, 119.36]106.78 [79.94, 144.31]0.367FGF23 C-terminal, RU/mL1.77 [0.82, 2.80]1.87 [1.58, 3.03]0.618Bioactive sclerostin, pmol/L85.87 [56.22, 118.78]57.34 [47.10, 66.34] 0.042 25OHD3, ng/mL33.01 [22.25, 41.94]24.75 [19.54, 39.24]0.392Bone mass/microarchitectureaBMD wb, g/cm21.15 [1.08, 1.22]1.15 [1.03, 1.23]0.786TBS1.34 [1.24, 1.47]1.47 [1.38, 1.51]0.082Bone strengthBMSi75.05 [67.65, 81.25]74.30 [72.73, 80.28]0.870Bone turnoverALP, U/L65.00 [46.50, 75.50]64.00 [55.75, 71.75]0.875BALP, µg/L13.21 [9.91, 16.53]15.77 [13.97, 19.02]0.080PINP intact, ng/mL40.63 [31.19, 55.02]66.11 [59.79, 76.37] 0.007 TRACP5b, U/L2.68 [2.24, 3.46]3.99 [2.70, 4.20]0.050Bold numbers indicate statistical significance at p < 0.05
Source: Mineral and Bone Phenotype in ADPKD Compared To Other CKD Etiologies. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this cross-sectional study, 81 patients with ADPKD, 15 with CKD of other etiologies, and 21 healthy individuals were included.
Source: Abstract.
All participants were adults and underwent screening for eligibility based on predefined inclusion and exclusion criteria specific to their respective groups.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease
Cross-sectional study · Calcified Tissue International · 2026
Original publication title
Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Autosomal dominant polycystic kidney disease (ADPKD) is a systemic ciliary disorder, yet the impact on bone health remains insufficiently defined. Given the expression of polycystins in osteocytes, osteoclasts and extracellular matrix, a disease-specific bone phenotype has been hypothesized. This study aimed to comprehensively characterize the bone phenotype in ADPKD across stages of chronic kidney disease (CKD) and Mayo Imaging Classification (MIC). In this cross-sectional study, 81 patients with ADPKD, 15 with CKD of other etiologies, and 21 healthy individuals were included.
Bone phenotype was assessed across four domains: bone metabolism biomarkers, bone turnover biomarkers, bone mass/microarchitecture (dual-energy X-ray absorptiometry with trabecular scoring (TBS)) and bone material strength (microindentation, BMSi). Z-score-based heat-maps were used to visualize stage-specific alterations, and multivariable regression analysis was applied to estimate model parameters. ADPKD patients consistently showed lower bone turnover, particularly PINP and in CKD G1-2 also BALP, while BMSi, BMD and TBS did not differ from healthy individuals. Across CKD stages, mineral abnormalities reflected the effect of declining eGFR, whereas stratification by MIC revealed less distinct patterns, indicating that the bone phenotype may be more closely linked to CKD progression than cystic burden in later CKD stages.
This first comprehensive analysis of the ADPKD bone phenotype reveals mineral disturbances, reduced bone turnover, and preserved bone mass and microarchitecture in early ADPKD. Bone alterations followed kidney function rather than MIC stage. Impact microindentation, BMSi, did not reveal any distinctive pattern in ADPKD.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-025-01471-w.
Authors’ abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a systemic ciliary disorder, yet the impact on bone health remains insufficiently defined. Given the expression of polycystins in osteocytes, osteoclasts and extracellular matrix, a disease-specific bone phenotype has been hypothesized. This study aimed to comprehensively characterize the bone phenotype in ADPKD across stages of chronic kidney disease (CKD) and Mayo Imaging Classification (MIC). In this cross-sectional study, 81 patients with ADPKD, 15 with CKD of other etiologies, and 21 healthy individuals were included.
Bone phenotype was assessed across four domains: bone metabolism biomarkers, bone turnover biomarkers, bone mass/microarchitecture (dual-energy X-ray absorptiometry with trabecular scoring (TBS)) and bone material strength (microindentation, BMSi). Z-score-based heat-maps were used to visualize stage-specific alterations, and multivariable regression analysis was applied to estimate model parameters. ADPKD patients consistently showed lower bone turnover, particularly PINP and in CKD G1-2 also BALP, while BMSi, BMD and TBS did not differ from healthy individuals. Across CKD stages, mineral abnormalities reflected the effect of declining eGFR, whereas stratification by MIC revealed less distinct patterns, indicating that the bone phenotype may be more closely linked to CKD progression than cystic burden in later CKD stages.
This first comprehensive analysis of the ADPKD bone phenotype reveals mineral disturbances, reduced bone turnover, and preserved bone mass and microarchitecture in early ADPKD. Bone alterations followed kidney function rather than MIC stage. Impact microindentation, BMSi, did not reveal any distinctive pattern in ADPKD.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-025-01471-w.
Publication and source details
Original title: Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease
Magdalena Jankowska; Per Magnusson; Malgorzata Debowska; Bengt Lindholm; Abdul Rashid Qureshi; Tomasz Lukaszuk; Alicja Dębska-Ślizień; Daniel Guido Fuster; Peter Stenvinkel; Mathias Haarhaus
Calcified Tissue International · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100004281Narodowe Centrum Nauki2018/30/M/NZ5/00480Jankowska MagdalenaRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:24:51.683153+00:00
DOI: 10.1007/s00223-025-01471-w · PMC12827306